Thrilled to be part of an amazing team organized by @HarvardDBMI @ZakKohane (incl @PeterAtMSR @MorganCheatham @GoldbergCarey Patti Brennan, and many others) writing today about "doing no harm and the most good" with medical #AI, in @NEJM_AI today!

Pushing the boundaries on undiagnosed patients beyond coding variants: non-coding splice variants at genome scale incl. compound hets w novel significance analsis @UDNconnect @UDNForg https://t.co/YYhETDl7AB Kudos @shilpanads et al.

BioMistral is a new 7B foundation model for medical domains, based on Mistral and further trained PubMed Central. - top open-source medical Large Language Model (LLM) in its weight class - Apache License - includes base models, fine tunes, and quantized versions.

“Mind blowing, boggling, outstanding” After decades of frustration and failed attempts, scientists might finally be on the cusp of developing therapies to restore immune ‘tolerance’ in conditions such as diabetes, lupus and multiple sclerosis

AI can help us to understand the data we’ve collected, and with enough of it, to generalize from them, within reason. In order to probe the limits of current scientific knowledge, however, we need data that we don’t already have https://t.co/qI0r7wwnaZ https://t.co/LTkty9sYeH

In an era of RNA delivery and therapeutics, we sought to “write” RNA molecules directly into messenger RNA to replace disease-causing exons or engineer synthetic proteins Our new work on RESPLICE enables fully programmable and highly efficient (45-90%) transcriptome engineering

The latest in the intersection of large language models and life science: virus sequences, virus proteins, and their function https://t.co/lyBtvkG1ug #AI @NatureMicrobiol @zflam94 @microbegrrl @EinsteinMed @steve_biller

Advances in artificial intelligence are at the heart of many of this year’s most exciting areas of technological innovation

Effect of mutations varies widely over a span of 50,000 generations. Some beneficial become harmful and vice versa but not at equal rates. @baym ™harvardDBMI et al. @scienceMagazine https://t.co/eHo6y6Y9c6 take the long view and dissect complex dialect of evolution.

Our back-to-back Review on "Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade" is out ( https://t.co/ul2TBUhMtU). Congrats to Cassia and Lee! Great working with the team in the @manoliskellis lab!

Delving into the future of #cancer treatment with new #ADC formats: Bispecific ADCs targeting multiple antigens, Dual-drug ADCs combining different cytotoxins, Probody-drug conjugates for enhanced tumor specificity, Immune-stimulating ADCs, Protein-degrader ADCs & other formats

The word "cure" hasn't been associated with treating autoimmune diseases. Until now, from advances in understanding the immune system and building tolerance to specific antigens, it's in the realm of the possible https://t.co/M9CVL0C5HC new feature @Nature

Excited to be part of the inaugural team at Arena BioWorks @arenabioworks and to work with the amazing scientists assembled there to advance human therapeutics with this new model for scientific innovation and discovery

Immensely proud to share our four papers on #SingleCell dissection of #Alzheimers Disease coming out in @CellCellPress today, reporting 2.3M #scRNA profiles and 850k #scATAC profiles across 427 post-mortem human brain samples from AD and non-AD donors in a wonderful

We learned a lot about human cell count and size from this recent @PNASNews paper https://t.co/i9qKqFOaVB Now made into a nice graphic https://t.co/JIxEH1B75D

Today Google announced #MedLM, a suite of new health-care-specific #AI models designed to help clinicians and researchers carry out complex studies, summarize doctor-patient interactions and more. https://t.co/ah14Dfbn3V

The Breakthrough of the Year 2023 @ScienceMagazine GLP-1 Drugs https://t.co/tAN4yqhBP0

The Gemini era is here. Thrilled to launch Gemini 1.0, our most capable & general AI model. Built to be natively multimodal, it can understand many types of info. Efficient & flexible, it comes in 3 sizes each best-in-class & optimized for different uses https://t.co/VUu1277bC2

What distinguishes an AI-first company? In this new @BessemerVP report, @stephenkraus and I share "Six Imperatives for AI-first Companies": heuristics for how startup founders, investors, and industry stakeholders can distill signal from noise in a crowded AI landscape.

President Clinton once asked me, ‘What’s Your Dream?’ I had to pause because no one had ever asked me that before. Then I said, my dream is to do what I did for myself but for millions of people around the world. I want to find new uses for all the drugs in your neighborhood